Company Analysis
Sign in

Nektar Therapeutics (NKTR)

Nasdaq: NKTR · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.3
◀ Past 4.0● Present 4.8▶ Future 4.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

474 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Nektar Therapeutics’s names, not what it holds today.

Patents granted
474
470 utility, 3 reissue, 1 design, 1976 to Dec 31, 2025
Granted in 2025
5
Against 5 in 2024 and 7 in 2023
Applications published
460
3 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals28
Macromolecular chemistry, polymers6
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Nektar Therapeutics its own name
US, as the owner printed on each patent. 3 more under the same name are not counted (printed in CA)
413 granted
269 published
Nektar Therapeutics its own name
named as the applicant on its applications, in US
0 granted
182 published
Inhale Therapeutic Systems, Inc. a former name
US, as the owner printed on each patent
61 granted
8 published
INHALE THERAPEUTIC SYSTEMS, a corporation of the State of California a former name
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 10, 202512,325,708Adenosine 2 receptor antagonistsOrganic fine chemistryNektar Therapeutics
Jun 10, 202512,324,828Conjugates of a factor VIII moiety having an oxime-containing linkagePharmaceuticalsNektar Therapeutics
Mar 11, 202512,247,059Conjugates of an IL-2 moiety and a polymerPharmaceuticalsNektar Therapeutics
Feb 25, 202512,233,104Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonistPharmaceuticalsNektar Therapeutics
Feb 4, 202512,214,045Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methodsPharmaceuticalsNektar Therapeutics
Aug 6, 202412,054,553Immunotherapeutic tumor treatment methodPharmaceuticalsNektar Therapeutics
Jul 16, 202412,036,283Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methodsPharmaceuticalsNektar Therapeutics
Jul 9, 202412,030,940Immunotherapeutic tumor treatment methodPharmaceuticalsNektar Therapeutics
Jun 25, 202412,016,952Methods of preparing a monodisperse oligo(ethylene glycol) reagent compositionPharmaceuticalsNektar Therapeutics
Mar 19, 202411,932,726Method of making releasable polymeric reagentsMacromolecular chemistry, polymersNektar Therapeutics
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0304641CONJUGATES OF AN IL-2 MOIETY AND A POLYMERPharmaceuticalsNektar Therapeutics
Aug 28, 20252025/0270273POLYMER ENGINEERED FORMS OF INTERFERON-GAMMA AND METHODS OF USEPharmaceuticalsNektar Therapeutics
Feb 13, 20252025/0049934DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONSPharmaceuticalsNektar Therapeutics
Dec 26, 20242024/0424115LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONISTS AND RELATED IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODSPharmaceuticalsNektar Therapeutics
Sep 12, 20242024/0299561HISTIDINE-SELECTIVE POLYMER REAGENTSPharmaceuticalsNektar Therapeutics
Nov 23, 20232023/0372500MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODSPharmaceuticalsNektar Therapeutics · patent 12,214,045 granted from it
Aug 3, 20232023/0241181CONJUGATES OF A FACTOR VIII MOIETY HAVING AN OXIME-CONTAINING LINKAGEPharmaceuticalsNektar Therapeutics · patent 12,324,828 granted from it
May 25, 20232023/0158164METHOD FOR ENHANCING CELLULAR IMMUNOTHERAPYPharmaceuticalsNektar Therapeutics
Apr 13, 20232023/0113413POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTSPharmaceuticalsNektar Therapeutics
Jul 28, 20222022/0235056ADENOSINE 2 RECEPTOR ANTAGONISTSPharmaceuticalsNektar Therapeutics · patent 12,325,708 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NKTR · research, not advice